Cited by 482Extracellular vesicles in diseaseMesenchymal stem cell researchPeriodontal Regeneration and Treatments

Mesenchymal stromal/stem cell (MSC)-Derived exosomes in clinical trials

Open access
Lotfy, Ahmed, AboQuella, Noha M., Wang, Hongjun·2023·Stem Cell Research & Therapy

Abstract

Mesenchymal stromal/stem cells (MSCs) are widely utilized in cell therapy because of their robust immunomodulatory and regenerative properties. Their paracrine activity is one of the most important features that contribute to their efficacy. Recently, it has been demonstrated that the production of various factors via extracellular vesicles, especially exosomes, governs the principal efficacy of MSCs after infusion in experimental models. Compared to MSCs themselves, MSC-derived exosomes (MSC-Exos) have provided significant advantages by efficiently decreasing unfavorable adverse effects, such as infusion-related toxicities. MSC-Exos is becoming a promising cell-free therapeutic tool and an increasing number of clinical studies started to assess the therapeutic effect of MSC-Exos in different diseases. In this review, we summarized the ongoing and completed clinical studies using MSC-Exos for immunomodulation, regenerative medicine, gene delivery, and beyond. Additionally, we summarized MSC-Exos production methods utilized in these studies with an emphasis on MSCs source, MSC-Exos isolation methods, characterization, dosage, and route of administration. Lastly, we discussed the current challenges and future directions of exosome utilization in different clinical studies as a novel therapeutic strategy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13287-023-03287-7

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The immunomodulatory function of MSC-Exos significantly declines when BMSCs undergo differentiation into osteoblasts.

    “However, the immunomodulatory function of MSC-Exos significantly declines when BMSCs undergo differentiation into osteoblasts.”

    From Hydrogel scaffold encapsulating MSC-Exos and ZIF-8 promotes bone regeneration via coordinating osteogenesis and immunomodulation (2025) · cites this paper as [31]

    The ‘Therapeutic potential of MSC-Exos in preclinical studies’ section says bone-marrow MSC exosomes can have immunomodulatory effects. The Introduction mentions exosome differences that may relate to MSC differentiation status, but neither passage reports a significant decline in immunomodulatory function when BMSCs differentiate into osteoblasts. Page numbers are unavailable in our copy. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 3

  1. [41]Hassanzadeh A Rahman HS Markov A Endjun JJ Zekiy AO Chartrand MS Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; Overview of development, challenges, and opportunities Stem Cell Res Therapy. 2021 12 1 297 10.1186/s13287-021-02378-7 PMC8138094 34020704 · DOI
  2. [75]Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid Disease. 2012 ed. Harris JR, editor. Dordrecht: Springer.
  3. [91]Rongjie Guo JJ, chenchen wang, Qi Liang, Kai Hu. MSC-EVs treat dry eye disease by regulating dendritic cells and promoting tissue repair. Invest Ophthalmol Vis Sci 2022;63(7):1978–A0308.

Cited by

Sorted by citations

Authors
Lotfy, A., AboQuella, N. M., & Wang, H.
Affiliations
  • Medical University of South Carolina (US)
  • Charité – Universitätsmedizin Berlin (DE)
Corresponding author
Lotfy, Ahmed
Venue
Stem Cell Research & Therapy
Published
2023-04-07
Volume
14
Issue
1
Pages
66-66
ISSN
1757-6512 (ISSN-L)
OpenAlex
W4362659077
Cited by
482
References
98
Citations by year
2026: 141 · 2025: 211 · 2024: 113 · 2023: 17
FWCI
12.69
Type
journal article
Language
en
Open access
Locations
  • Stem Cell Research & Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institute of Diabetes and Digestive and Kidney Diseases (1R01DK105183, DK120394, DK118529)
  • U.S. Department of Veterans Affairs (I01BX004536)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Health Sciences › Medicine › Urology › Periodontal Regeneration and Treatments
Keywords
mesenchymal stem cells, exosomes, cell-free therapy, clinical trials, immunomodulation, regenerative medicine, gene delivery, extracellular vesicles, exosome isolation, route of administration, dosage, infusion-related toxicity, paracrine signaling
MeSH terms
Extracellular Vesicles, Exosomes, Immunomodulation, Mesenchymal Stem Cells, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review